VCM
ACRS icon

Versant Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Versant Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-164
Closed – – 1274
2019
Q4 		$0 Buy
+164
New +$272 ﹤0.01% 1331

Other funds holding ACRS

MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Versant Capital Management's ACRS Position: Q1 2020 in Review

Versant Capital Management sold out of Aclaris Therapeutics (ACRS) in Q1 2020, closing a stake of 164 shares.

Versant Capital Management first reported a position in ACRS in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 71 funds tracked by Wall St. Rank hold ACRS as of Q1 2020.

  • Versant Capital Management reported no remaining Aclaris Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Versant Capital Management sold 164 Aclaris Therapeutics shares in Q1 2020.
  • Versant Capital Management first reported a position in Aclaris Therapeutics in Q4 2019 and held it in 1 quarter.
  • Versant Capital Management's Aclaris Therapeutics position peaked at $0 in Q4 2019.
  • 71 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2020.

Based on Versant Capital Management's 13F filing for Q1 2020, filed 17 Apr 2020.